 Inclusion Criteria: - Subjects must have signed written informed consent - Be on Procrit QW or Q2W for a minimum of 8 weeks - Must currently be on a stable dose of Procrit defined as less than 25 change in Procrit dose over the 4 week period immediately prior to enrollment, with no missed doses - Have Hgb 10-12 gdL for at least 4 weeks prior to study start - Have 15 less than GFR less than 89 mLmin1.73 m2 Exclusion Criteria: - Currently receiving investigational erythropoietic agents - Self-injecting at home with Procrit - Expected to initiate renal replacement therapy dialysis or transplantation within 1 year of study start - Have less than 1 year life expectancy 